|
US8119159B2
(en)
|
1999-02-22 |
2012-02-21 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
|
US7658938B2
(en)
|
1999-02-22 |
2010-02-09 |
Merrion Reasearch III Limited |
Solid oral dosage form containing an enhancer
|
|
PL1787658T3
(pl)
|
2005-11-10 |
2012-08-31 |
Italfarmaco Spa |
Formulacje o przedłużonym uwalnianiu analogów somatostatyny będących inhibitorami hormonu wzrostu
|
|
ITMI20060618A1
(it)
*
|
2006-03-31 |
2007-10-01 |
Enitecnologie Spa |
Procedimento per la preparazione di nanoemulsioni acqua ion olio e olio in acqua
|
|
CA2648594C
(en)
|
2006-04-07 |
2012-10-16 |
Merrion Research Iii Limited |
Solid oral dosage form containing an enhancer
|
|
KR100816065B1
(ko)
*
|
2006-11-27 |
2008-03-24 |
동국제약 주식회사 |
초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
|
|
RU2362544C2
(ru)
*
|
2007-04-09 |
2009-07-27 |
Закрытое акционерное общество "Санкт-Петербургский институт фармации" |
Наноэмульсия с биологически активными веществами
|
|
EP2207427B1
(en)
*
|
2007-10-04 |
2017-05-03 |
Medical Instill Technologies, Inc. |
Apparatus and method for formulating and aseptically filling liquid products
|
|
JP2011519928A
(ja)
*
|
2008-05-07 |
2011-07-14 |
メリオン・リサーチ・Ｉｉｉ・リミテッド |
ペプチドの組成物及びその調製方法
|
|
TWI536999B
(zh)
|
2010-01-13 |
2016-06-11 |
艾普森藥品公司 |
製備持續釋放生長激素抑制素類似物之醫藥組成物之方法
|
|
US9089484B2
(en)
|
2010-03-26 |
2015-07-28 |
Merrion Research Iii Limited |
Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
|
|
JP2013523162A
(ja)
|
2010-04-06 |
2013-06-17 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法
|
|
AU2011261434B2
(en)
|
2010-06-02 |
2015-11-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
|
US9107822B2
(en)
|
2010-09-03 |
2015-08-18 |
Santen Sas |
Water-in oil type emulsion for treating a disease of the eye
|
|
AU2011298298B2
(en)
|
2010-09-03 |
2016-04-21 |
Santen Sas |
A water-in-oil type emulsion for treating a disease of the eye
|
|
PL2425814T3
(pl)
|
2010-09-03 |
2013-11-29 |
Santen Sas |
Emulsja typu woda-w-oleju do leczenia choroby oka
|
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
JP2014501784A
(ja)
|
2011-01-07 |
2014-01-23 |
メリオン・リサーチ・Ｉｉｉ・リミテッド |
経口投与用の鉄の医薬組成物
|
|
CA3217805A1
(en)
|
2011-03-29 |
2012-10-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of tmprss6 gene
|
|
EP3354343B1
(en)
|
2011-06-02 |
2023-09-06 |
President and Fellows of Harvard College |
Methods and uses for ex vivo tissue culture systems
|
|
WO2012177906A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
KR102232287B1
(ko)
|
2011-06-21 |
2021-03-29 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
|
|
EP4134433A1
(en)
|
2011-06-23 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
WO2013003112A1
(en)
|
2011-06-27 |
2013-01-03 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
|
CN102552138A
(zh)
*
|
2012-02-28 |
2012-07-11 |
大连医科大学 |
口服羟丝肽w/o微乳制剂及其制备方法
|
|
CN102552187B
(zh)
*
|
2012-02-28 |
2015-10-28 |
大连医科大学 |
口服羟丝肽纳米粒及其制备方法
|
|
AU2013230085B2
(en)
*
|
2012-03-05 |
2016-04-28 |
Archer Daniels Midland Company |
Microemulsions and uses thereof as delivery systems
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
EP3336187A1
(en)
|
2012-12-05 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Pcsk9 irna compositions and methods of use thereof
|
|
KR102605775B1
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법
|
|
EP2978446B1
(en)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antibody for use in treating alzheimer's disease
|
|
TW201515650A
(zh)
|
2013-05-06 |
2015-05-01 |
艾爾妮蘭製藥公司 |
遞送經脂質調配之核酸分子之劑量及方法
|
|
MX379208B
(es)
|
2013-05-22 |
2025-03-10 |
Alnylam Pharmaceuticals Inc |
Composiciones de arni de serpina1 y sus metodos de uso.
|
|
EP3828276A1
(en)
|
2013-05-22 |
2021-06-02 |
Alnylam Pharmaceuticals, Inc. |
Tmprss6 irna compositions and methods of use thereof
|
|
JP6800748B2
(ja)
|
2013-06-14 |
2020-12-16 |
アカマラ セラピューティクス、インコーポレイテッド |
脂質ベース白金化合物およびナノ粒子
|
|
EP2823808A1
(en)
|
2013-07-09 |
2015-01-14 |
Ipsen Pharma S.A.S. |
Pharmaceutical composition for a sustained release of lanreotide
|
|
EP2832361A1
(en)
*
|
2013-07-29 |
2015-02-04 |
Ipsen Pharma S.A.S. |
Aqueous sustained release compositions of LHRH analogs
|
|
TWI669393B
(zh)
|
2013-10-02 |
2019-08-21 |
艾爾妮蘭製藥公司 |
抑制ｌｅｃｔ２基因表現之組合物及方法
|
|
LT3052628T
(lt)
|
2013-10-04 |
2020-09-10 |
Alnylam Pharmaceuticals, Inc. |
Kompozicijos ir būdai alas1 geno raiškai nuslopinti
|
|
AU2014362262B2
(en)
|
2013-12-12 |
2021-05-13 |
Alnylam Pharmaceuticals, Inc. |
Complement component iRNA compositions and methods of use thereof
|
|
EP3105331B1
(en)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
|
|
CN112301031A
(zh)
|
2014-05-22 |
2021-02-02 |
阿尔尼拉姆医药品有限公司 |
血管紧张素原(AGT)iRNA组合物及其使用方法
|
|
KR101686986B1
(ko)
|
2014-07-28 |
2016-12-16 |
에스케이케미칼주식회사 |
류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
|
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
AU2015350120B2
(en)
|
2014-11-17 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
|
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
|
CA2974369A1
(en)
|
2015-01-20 |
2016-07-28 |
The Children's Medical Center Corporation |
Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
|
|
JP7211704B2
(ja)
|
2015-01-29 |
2023-01-24 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
|
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
WO2016164746A1
(en)
|
2015-04-08 |
2016-10-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
TWI723986B
(zh)
|
2015-04-13 |
2021-04-11 |
美商阿尼拉製藥公司 |
類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其用途方法
|
|
AU2016257996A1
(en)
|
2015-05-06 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Factor XII (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA compositions and methods of use thereof
|
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
EA201890619A1
(ru)
|
2015-09-02 |
2018-09-28 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
|
EP3362458A1
(en)
|
2015-10-16 |
2018-08-22 |
Invictus Oncology Pvt. Ltd. |
Fluorescent anticancer platinum drugs
|
|
ES3041380T3
(en)
|
2015-12-07 |
2025-11-11 |
Genzyme Corp |
Methods and compositions for treating a serpinc1-associated disorder
|
|
WO2017100542A1
(en)
|
2015-12-10 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
TWI790217B
(zh)
|
2016-12-16 |
2023-01-21 |
美商阿尼拉製藥公司 |
使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
|
|
JP2020530442A
(ja)
|
2017-07-10 |
2020-10-22 |
ジェンザイム・コーポレーション |
血友病を有する対象の出血事象を処置するための方法および組成物
|
|
AU2018301477A1
(en)
|
2017-07-13 |
2020-02-27 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
|
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
|
EP3710587A1
(en)
|
2017-11-16 |
2020-09-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
CN111727252A
(zh)
|
2017-12-18 |
2020-09-29 |
阿尔尼拉姆医药品有限公司 |
高速泳动族盒-1（HMGB1）iRNA组合物及其使用方法
|
|
EP3837367A1
(en)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
EP3853364A1
(en)
|
2018-09-18 |
2021-07-28 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk) irna compositions and methods of use thereof
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
EP4013870A1
(en)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
|
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
CA3155921A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
BR112022011417A2
(pt)
|
2019-12-13 |
2022-08-30 |
Alnylam Pharmaceuticals Inc |
Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas
|
|
JP2021116306A
(ja)
*
|
2020-01-28 |
2021-08-10 |
ロート製薬株式会社 |
油性組成物
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
CA3170377A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
JP2023519274A
(ja)
|
2020-03-26 |
2023-05-10 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
コロナウイルスｉＲＮＡ組成物およびその使用方法
|
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
US20230295622A1
(en)
|
2020-04-06 |
2023-09-21 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
|
WO2021206917A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4133077A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
US20230159933A1
(en)
|
2020-04-07 |
2023-05-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
EP4143319A1
(en)
|
2020-04-27 |
2023-03-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
|
US20230183707A1
(en)
|
2020-05-21 |
2023-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
CN116075592A
(zh)
|
2020-06-09 |
2023-05-05 |
阿尔尼拉姆医药品有限公司 |
用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
|
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
WO2022076291A1
(en)
|
2020-10-05 |
2022-04-14 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
EP4232581A1
(en)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
CA3201452A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
JP7673944B2
(ja)
*
|
2020-12-23 |
2025-05-09 |
国立大学法人東海国立大学機構 |
破骨細胞増殖性疾患の予防又は治療剤
|
|
WO2022174000A2
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
CN117222739A
(zh)
|
2021-02-25 |
2023-12-12 |
阿尔尼拉姆医药品有限公司 |
朊病毒蛋白(prnp)irna组合物和其使用方法
|
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
TW202305134A
(zh)
|
2021-03-29 |
2023-02-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
|
|
EP4321152A4
(en)
*
|
2021-04-08 |
2025-05-21 |
Tionlab Therapeutics |
Sustained-release lipid preconcentrate
|
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法
|
|
TW202308663A
(zh)
|
2021-06-04 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
人類染色體９開讀框７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ劑組成物及其使用方法
|
|
EP4373934A1
(en)
|
2021-07-19 |
2024-05-29 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
|
EP4395790A2
(en)
|
2021-08-31 |
2024-07-10 |
Alnylam Pharmaceuticals, Inc. |
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof
|
|
EP4423272A2
(en)
|
2021-10-29 |
2024-09-04 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
MA71735A
(fr)
|
2022-09-15 |
2025-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation
|